Compare TNET & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNET | NAMS |
|---|---|---|
| Founded | 1988 | 2019 |
| Country | United States | Netherlands |
| Employees | 2700 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.8B |
| IPO Year | 2000 | 2022 |
| Metric | TNET | NAMS |
|---|---|---|
| Price | $62.41 | $21.61 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 16 |
| Target Price | ★ $66.20 | $50.65 |
| AVG Volume (30 Days) | 251.2K | ★ 1.9M |
| Earning Date | 10-28-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.81% | N/A |
| EPS Growth | N/A | ★ 32.81 |
| EPS | ★ 3.05 | N/A |
| Revenue | ★ $5,010,000,000.00 | $22,503,000.00 |
| Revenue This Year | N/A | $29.51 |
| Revenue Next Year | $3.80 | $383.46 |
| P/E Ratio | $20.97 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $33.67 | $21.02 |
| 52 Week High | $73.08 | $42.21 |
| Indicator | TNET | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 38.53 | 36.31 |
| Support Level | $59.61 | $21.02 |
| Resistance Level | $64.37 | $37.26 |
| Average True Range (ATR) | 1.87 | 1.28 |
| MACD | -0.44 | 0.19 |
| Stochastic Oscillator | 8.54 | 16.02 |
Trinet Group Inc provides human resources solutions for small and medium-sized businesses through technology-enabled services. Its offerings include human capital expertise, employee benefits such as health insurance and retirement plans, payroll and payroll tax administration, risk mitigation, and compliance consulting. The company provides its services through professional employer organization (PEO) services delivered via a co-employment model, as well as administrative services organization (ASO) offerings. The majority of the company's revenue is derived from the insurance-related billings and administrative fees collected from PEO clients.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.